Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study

被引：0
作者：
Tan, X. [1 ]
Wu, Z. [1 ]
Wang, Y. [1 ]
Yao, K. [1 ]
机构：
[1] Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.354
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
218P
引用
收藏
页码：S1560 / S1560
页数：1
相关论文
共 50 条
  • [41] Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience
    Mitra, N.
    Monk, J. P., III
    Pohar, K. S.
    Shabsigh, A.
    Sharp, D. S.
    Abaza, R.
    Box, G. N.
    Zynger, D. L.
    Clinton, S. K.
    Mortazavi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [42] IMPACT OF METHOD FOR MODELLING DISTANT RECURRENCE (DR) ON COST-EFFECTIVENESS (CE) OF NIVOLUMAB (NIVO) AS AN ADJUVANT TREATMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA (MIUC) PATIENTS WITH HIGH RISK OF RECURRENCE IN FRANCE
    Bonastre, J.
    Negrier, S.
    Colrat, F.
    Chamielec, C.
    Teitsson, S.
    Knight, C.
    Ni, L.
    Chevalier, J.
    Gaudin, A. F.
    Roupret, M.
    Branchoux, S.
    VALUE IN HEALTH, 2022, 25 (12) : S9 - S9
  • [43] A retrospective real-world study of disitamab vedotin combined with tislelizumab versus chemotherapy in patients with previously untreated metastatic urothelial carcinoma.
    Se, Han
    Gui, Xiaomeng
    Wang, Lin
    Jing, Jing
    Si, Riguleng
    Li, Haojing
    Lv, Dongchen
    Li, Jia
    Chi, Ning
    Li, Sanxiang
    Yang, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [44] Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience.
    Mitra, N.
    Monk, J. P.
    Pohar, K. S.
    Shabsigh, A.
    Sharp, D. S.
    Abaza, R.
    Box, G. N.
    Zynger, D. L.
    Vandlik, S. L.
    Bhinder, A. S.
    Olencki, T.
    Bahnson, R. R.
    Clinton, S. K.
    Mortazavi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials
    Oscar-Thompson, Laura
    Riveros, Carlos
    Sonpavde, Guru
    Apolo, Andrea B.
    Lalani, Aly-Khan A.
    Wallis, Christopher J. D.
    Satkunasivam, Raj
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03) : 156 - 163
  • [46] Effectiveness and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: A preliminary report of real-world data from a single institution in Japan
    Yasuda, Y.
    Urasaki, T.
    Oki, R.
    Takemura, K.
    Yoneoka, Y.
    Fujiwara, R.
    Oguchi, T.
    Numao, N.
    Yonese, J.
    Yuasa, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1520 - S1520
  • [47] EFFICACY AND SAFETY RESULTS FROM REAL-WORLD STUDIES EVALUATING ADJUVANT TREATMENT AFTER RADICAL RESECTION (RR) OF MUSCLE INVASIVE UROTHELIAL CARCINOMA (MIUC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Trip, A. M.
    Shree, A.
    Rekowska, D.
    Teitsson, S.
    Broughton, E.
    May, J. R.
    Kurt, M.
    Alleman, C.
    VALUE IN HEALTH, 2022, 25 (01) : S33 - S33
  • [48] POST DISTANT RECURRENCE (DR) SURVIVAL OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA (MIUC) PATIENTS WITH PRIOR RADICAL CYSTECTOMY (RC): ANALYSIS OF A FLATIRON REAL-WORLD COHORT MATCHED TO CHECKMATE-274
    Lambton, M.
    Nickel, K.
    Patel, M. Y.
    Kurt, M.
    Teitsson, S.
    Kroep, S.
    Geynisman, D. M.
    VALUE IN HEALTH, 2023, 26 (06) : S19 - S19
  • [49] Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial
    Tomita, Yoshihiko
    Kobayashi, Ko
    Kimura, Go
    Oya, Mototsugu
    Uemura, Hirotsugu
    Nishiyama, Hiroyuki
    Galsky, Matthew D.
    Nasroulah, Federico
    Collette, Sandra
    Broughton, Edward
    Unsal-Kacmaz, Keziban
    Kamisuki, Yukinori
    Bajorin, Dean F.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (01) : 16 - 25
  • [50] Phase II clinical study of tislelizumab combined with nab-paclitaxel (TRUCE-01) for muscle-invasive urothelial bladder carcinoma: Bladder preservation subgroup analysis.
    Niu, Yuanjie
    Hu, Hailong
    Wang, HaiTao
    Tian, Dawei
    Zhao, Gangjian
    Shen, Chong
    Wu, Zhouliang
    Da, La
    Zhan, Xuejian
    Huang, Shiwang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345